Cargando…

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches

Drug designing is high-priced and time taking process with low success rate. To overcome this obligation, computational drug repositioning technique is being promptly used to predict the possible therapeutic effects of FDA approved drugs against multiple diseases. In this computational study, protei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassan, Mubashir, Shahzadi, Saba, Yasir, Muhammad, Chun, Wanjoo, Kloczkowski, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590448/ https://www.ncbi.nlm.nih.gov/pubmed/37865690 http://dx.doi.org/10.1038/s41598-023-45347-1

Ejemplares similares

Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies
por: Hassan, Mubashir, et al.
Publicado: (2022)

Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing’s Sarcoma: A Composite Review
por: Hassan, Mubashir, et al.
Publicado: (2023)

Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
por: Afzaal, Hasan, et al.
Publicado: (2022)

Larval Zebrafish Model for FDA-Approved Drug Repositioning for Tobacco Dependence Treatment
por: Cousin, Margot A., et al.
Publicado: (2014)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Tyrosinase Inhibitors Naturally Present in Plants and Synthetic Modifications of These Natural Products as Anti-Melanogenic Agents: A Review
por: Hassan, Mubashir, et al.
Publicado: (2023)

Therapeutic Implications of microRNAs in Depressive Disorders: A Review
por: Hassan, Mubashir, et al.
Publicado: (2022)

Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
por: Fernández-Martínez, Juan Luis, et al.
Publicado: (2020)

Nature’s Own Pharmacy: Mushroom-Based Chemical Scaffolds and Their Therapeutic Implications
por: Hassan, Mubashir, et al.
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
por: Varadharajan, Ashvin, et al.
Publicado: (2023)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Mechanistic insights into TNFR1/MADD death domains in Alzheimer’s disease through conformational molecular dynamic analysis
por: Hassan, Mubashir, et al.
Publicado: (2021)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Investigating drug repositioning opportunities in FDA drug labels through topic modeling
por: Bisgin, Halil, et al.
Publicado: (2012)

Molecular docking analysis of FDA approved drugs with the glycoprotein from Junin and Machupo viruses
por: Malhotra, Himani, et al.
Publicado: (2022)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Recently FDA-approved drug: A new hope for vitiligo patients?
por: Siddiq, Mohammad Arham, et al.
Publicado: (2022)

Colchicine as a novel drug for the treatment of osteosarcoma through drug repositioning based on an FDA drug library
por: Oh, Jisun, et al.
Publicado: (2022)

In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations
por: Qayed, Wesam S., et al.
Publicado: (2022)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

IDAAPM: integrated database of ADMET and adverse effects of predictive modeling based on FDA approved drug data
por: Legehar, Ashenafi, et al.
Publicado: (2016)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Water Networks in Complexes between Proteins and FDA-Approved Drugs
por: Samways, Marley L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rhdbo54f0n0u94efd4gmkfivio